Associations Between Symptoms, Donor Characteristics and IgG Antibody Response in 2082 COVID-19 Convalescent Plasma Donors

Marieke Vinkenoog, Maurice Steenhuis, Anja ten Brinke, J. G. Coen van Hasselt, Mart P. Janssen, Matthijs van Leeuwen, Francis Swaneveld, Hans Vrielink, Leo van de Watering, Franke A. Quee, Katja van den Hurk, Theo Rispens, Boris M. Hogema, C. Ellen van der SchootFrontiers in Immunology 2022 · DOI

Abstract

While many studies have explored how patient characteristics influence COVID-19 severity, the relationship between these factors and long-term SARS-CoV-2 antibody levels has remained less clear. This retrospective observational study analyzed 11,118 longitudinal IgG antibody measurements from 2,082 unique COVID-19 convalescent plasma (CCP) donors. Using linear mixed-effects modeling, researchers found that antibody responses are significantly associated with body mass index (BMI), age, and sex. Notably, antibody decay was faster in male donors (62-day half-life) compared to female donors (72-day half-life). Furthermore, the study identified specific symptom clusters—such as fever and dyspnoea—that correlate with higher peak IgG concentrations, while others, like anosmia and headache, correlate with lower peaks.

Introduction: The Challenge of Convalescent Plasma

Early in the COVID-19 pandemic, Convalescent Plasma (CCP) emerged as a promising treatment for severe cases. However, clinicians quickly observed a massive variation in antibody levels among recovered donors. Some individuals maintained high, long-lasting titers, while others saw their antibody levels drop below detectable limits within weeks. This study seeks to move beyond simple binary (positive/negative) results to understand the underlying kinetics of the immune response. By identifying which donor characteristics and symptoms predict a robust and lasting antibody response, researchers can better identify "super-donors" and gain insight into the body's long-term defense mechanisms.

Methodology: Modeling Immune Kinetics

The researchers employed a linear mixed-effects model to analyze the longitudinal data. This statistical approach is particularly effective for such datasets because it accounts for both "fixed effects" (general trends like age or BMI) and "random effects" (individual variations in starting antibody levels and decay rates).

Key technical parameters included:

  • Antibody Target: IgG antibodies against the SARS-CoV-2 Receptor Binding Domain (RBD).
  • Normalization: IgG levels were log-transformed to normalize the data distribution.
  • Baseline: "Time zero" was established at 20 days post-symptom onset to estimate peak concentration.
  • Analysis Steps: The team utilized a three-step model, starting with a null model (time only), adding donor demographics, and finally incorporating clinical symptoms to determine which factors significantly improved predictive power.

Dataset and Population Characteristics

The study utilized a massive longitudinal dataset from Sanquin, the sole blood bank in the Netherlands. The cohort consisted of 2,082 unique donors who provided at least three consecutive measurements, allowing for accurate calculations of antibody half-life.

Distribution of peak Anti-RBD IgG concentrations (A) and antibody half-lives (B) among 2,082 donors.

Key Insights: The "Anatomy of Infection" Hypothesis

One of the most striking findings is the correlation between the location of symptoms and the resulting antibody peak. Symptoms associated with the upper respiratory tract—such as headache, nasal cold, and loss of smell (anosmia)—were linked to lower peak antibodies. Conversely, symptoms suggesting systemic inflammation or deeper lung involvement—such as fever, shortness of breath (dyspnoea), and diarrhea—were linked to significantly higher antibody peaks. This suggests that a more invasive or systemic infection triggers a more robust initial immune response.

Summary of Results

  • Antibody Half-life: The average half-life of IgG antibodies was 66 days. However, a clear sex-based difference emerged: 62 days for men versus 72 days for women. While men often had higher initial peaks (likely due to more severe initial illness), their levels decayed faster.
  • Hospitalization: Donors who had been hospitalized showed peak IgG levels roughly 77.8 AU/ml higher than non-hospitalized donors, though they also experienced a faster decay rate (48-day half-life for hospitalized men).
  • Demographics: Higher BMI and older age were both positively correlated with higher peak IgG, reinforcing the idea that a more "stressed" immune system during the acute phase results in a higher antibody ceiling.
  • Predictive Power: Combined, donor characteristics and symptoms explained approximately 25% of the variation in peak antibody levels between individuals.

Limitations and Future Directions

The study acknowledges several limitations, including potential recall bias from self-reported symptoms and a "healthy donor bias," as the cohort only included individuals well enough to donate plasma. Furthermore, the study measured total IgG levels rather than neutralizing capacity or T-cell responses. Future research will be necessary to determine if these decay rates directly correlate with the risk of reinfection and to help blood banks more efficiently pre-screen for high-quality donors.

Summary updated

Abstract

Many studies already reported on the association between patient characteristics on the severity of COVID-19 disease outcome, but the relation with SARS-CoV-2 antibody levels is less clear. To investigate this in more detail, we performed a retrospective observational study in which we used the IgG antibody response from 11,118 longitudinal antibody measurements of 2,082 unique COVID convalescent plasma donors. COVID-19 symptoms and donor characteristics were obtained by a questionnaire. Antibody responses were modelled using a linear mixed-effects model. Our study confirms that the SARS-CoV-2 antibody response is associated with patient characteristics like body mass index and age. Antibody decay was faster in male than in female donors (average half-life of 62 versus 72 days). Most interestingly, we also found that three symptoms (headache, anosmia, nasal cold) were associated with lower peak IgG, while six other symptoms (dry cough, fatigue, diarrhoea, fever, dyspnoea, muscle weakness) were associated with higher IgG concentrations.
BibTeX
@inproceedings{vinkenoog2022associations,
  author = {Marieke Vinkenoog and Maurice Steenhuis and Anja ten Brinke and J. G. Coen van Hasselt and Mart P. Janssen and Matthijs van Leeuwen and Francis Swaneveld and Hans Vrielink and Leo van de Watering and Franke A. Quee and Katja van den Hurk and Theo Rispens and Boris M. Hogema and C. Ellen van der Schoot},
  title = {{Associations Between Symptoms, Donor Characteristics and IgG Antibody Response in 2082 COVID-19 Convalescent Plasma Donors}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.821721},
}
Figure